Towards Personalized Intervention for Alzheimer’s Disease

  title={Towards Personalized Intervention for Alzheimer’s Disease},
  author={Xing Peng and Peiqi Xing and Xiuhui Li and Ying Qian and Fuhai Song and Zhouxian Bai and Guangchun Han and Hongxing Lei},
  journal={Genomics, Proteomics \& Bioinformatics},
  pages={289 - 297}
Alzheimer’s disease (AD) remains to be a grand challenge for the international community despite over a century of exploration. A key factor likely accounting for such a situation is the vast heterogeneity in the disease etiology, which involves very complex and divergent pathways. Therefore, intervention strategies shall be tailored for subgroups of AD patients. Both demographic and in-depth information is needed for patient stratification. The demographic information includes primarily APOE… Expand
Personalized treatment interventions: nonpharmacological and natural treatment strategies in Alzheimer’s disease
ABSTRACT Introduction: Alzheimer’s disease (AD) is a slow, irreversible, progressive, complex, and fatal neurodegenerative disorder. Available pharmacological treatment, known for almost two decades,Expand
Personalizing the Care and Treatment of Alzheimer’s Disease: An Overview
A comprehensive overview of the literature on AD, the current and potential therapy of both cognitive symptoms as well as BPSD, with a special focus on gut microbiota and epigenetic modifications as new emerging drug targets is provided. Expand
Lifestyle intervention to prevent Alzheimer’s disease
Results revealed that lifestyle interventions have significant effects and the conclusion is that combination of early lifestyle interventions can decrease the risk of developing AD. Expand
Evaluation of Peripheral Immune Dysregulation in Alzheimer's Disease and Vascular Dementia.
This is the first attempt to conduct personalized evaluation of peripheral immune dysregulation in AD and VaD patients and found that there existed a wide dynamic range for the expression of these immune genes in peripheral blood even within the control group. Expand
The “rights” of precision drug development for Alzheimer’s disease
Attention to disciplined drug development will increase the likelihood of success, decrease the risks associated with AD drug development, enhance the ability to attract investment, and make it more likely that new therapies will become available to those with or vulnerable to the emergence of AD. Expand
Peptides as Potential Therapeutics for Alzheimer’s Disease
This review focuses on peptides that inhibit toxic Aβ oligomerization, Aβ aggregation into fibrils, or stabilize Aβ peptides in non-toxic oligomers, and discusses their potential for AD treatment. Expand
A strategy to find novel candidate anti-Alzheimer’s disease drugs by constructing interaction networks between drug targets and natural compounds in medical plants
Natural compounds from TCM provide a broad prospect for the screening of anti-AD drugs, especially the plants from two genera Panax and Morus, which are abundantly found in plants used for treating AD in China. Expand
Communication Engineering Meets Medical Science: The Advanced Targeted Nanomedical Solution
With the rise in global population, the increase in the number of medically challenging diseases and the low number (as well as uneven distribution) of medical personnel, there is the need for a newExpand
Prevention and reversal of Alzheimer's disease: treatment protocol
The scope of the study is to develop a protocol to prevent and reverse Alzheimer's Disease. There are three components to the data file. The main component is a narrative monograph, and is presentedExpand
Spore powder of Ganoderma lucidum for the treatment of Alzheimer disease
The results of this study did not find the promising efficacy of SPGL for the treatment of AD after 6-week treatment, and this may be because of the relative short-term of intervention. Expand


Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Amyloid-beta (Aβ) plays a pivotal role in Alzheimer’s disease (AD) pathogenesis, and is the most promising disease-modifying target for AD. A succession of failures in Aβ-targeting clinical trials,Expand
Precision Medicine for Alzheimer’s Disease Prevention
This review discusses examples of a “one-size-fits-all” versus clinical precision medicine AD prevention strategy, in which the precision medicine approach considers two genes that can be commercially sequenced for polymorphisms associated with AD, apolipoprotein E (APOE), and methylenetetrahydrofolate reductase (MTHFR). Expand
Immunotherapeutic Approaches for Alzheimer’s Disease
For greater efficacy the next generation of vaccines needs to focus more on concurrently targeting all the intermediate toxic conformers of oligomeric Aβ and tau species. Expand
Beyond amyloid: Getting real about nonamyloid targets in Alzheimer's disease
The Alzheimer's Association's Research Roundtable convened a meeting in April 2012 to move beyond amyloid and explore AD as a complex multifactorial disease, with the goal of using a more inclusive perspective to identify novel treatment strategies. Expand
Preventing Alzheimer’s Disease
New mechanisms targeting the hallmark pathology of Alzheimer’s disease are currently under investigation, including immunotherapy and secretase modulation, targeted at reducing the amyloid burden, for which the authors await the results. Expand
Perturbation of the transcriptome: implications of the innate immune system in Alzheimer's disease.
The combination of transcriptome studies and other types of studies has further elucidated the roles of specific immune pathways in distinct cell types during AD development and highlighted the critical contributions from immune genes such as TREM2. Expand
When will Alzheimer's disease be cured? A pharmaceutical perspective.
  • M. Townsend
  • Medicine
  • Journal of Alzheimer's disease : JAD
  • 2011
Some of the details of recent clinical trials are explored, it is essential to understand the expectations of regulatory agencies such as the FDA and EMA to obtain approval, and some of the essential gaps in scientific understanding about the disease process are covered. Expand
A blood-based predictor for neocortical Aβ burden in Alzheimer’s disease: results from the AIBL study
Results show that a panel of blood- based biomarkers is able to accurately predict NAB, supporting the hypothesis for a relationship between a blood-based signature and Aβ accumulation, therefore, providing a platform for developing a population-based screen. Expand
Brain Food for Alzheimer-Free Ageing: Focus on Herbal Medicines.
  • H. Hügel
  • Medicine
  • Advances in experimental medicine and biology
  • 2015
The focus of this review is to critically examine the evidence, impact, influence and mechanisms of natural products as chemopreventive agents which induce therapeutic outcomes that modulate the aggregation process of beta-amyloid (Aβ), providing measureable cognitive benefits in the aging process. Expand
Genetic Factors in Alzheimer's Disease
Some of the major etiological hypotheses for AD are reviewed, with an emphasis on the involvement of genetic factors. Expand